92 results about "Aging cell" patented technology

The invention relates to a repairing composition for reducing senescence cell cumulant and a preparation method and application thereof, and the repairing composition comprises the following components in parts by weight: 0.01-7.0 parts of probiotic pellets PDRN, 0.01-3.0 parts of microspheroidized PDRN, 0.01-10.0 parts of a ginseng root extract, 0.01-10.0 parts of red ginseng fermented vesicles, a thickening agent, functional components and water. Under a formula system of a thickening agent and functional components, the probiotic pellets PDRN, the microspheroidized PDRN, the ginseng root extract and the red ginseng fermented vesicles are added, and all the components have a synergistic effect, so that the composition can penetrate into skin to achieve the effect of accurately repairing mitochondrial dysfunction, can directly remove senescent cells, reduces the senescent cell cumulant in a body in multiple ways, and has a good effect on repairing mitochondrial dysfunction. Therefore, the prepared skin care composition can effectively delay skin aging.

This invention discloses a fusion protein targeting the urokinase-type plasminogen activator receptor and its application in the field of anti-aging. The fusion protein is composed of a hepatocyte growth factor active domain and a humanized anti-uPAR single-domain antibody linked by a flexible linker peptide, and its specific amino acid sequence is SEQ ID NO:3. This fusion protein can specifically bind to uPAR, which is highly expressed on the surface of senescent cells, with intramolar affinity, achieving targeted delivery of the hepatocyte growth factor active domain. In vitro experiments have demonstrated that this protein can significantly reverse the aging phenotype of human fibroblasts, effectively reduce aging-related β-galactosidase activity, p16INK4a protein expression, and interleukin-6 secretion, and promote cell proliferation. In a rapidly aging mouse model, this protein can systematically improve age-related physiological functional decline. The fusion protein of this invention achieves specific targeting and efficient treatment of senescent cells, providing a new solution for the development of anti-aging drugs.

The present invention relates to the use of GRP78 and peptides similar thereto or nucleic acids encoding the same. The peptides or nucleic acids according to the present invention can increase the expression of biomarkers having reduced expression in senescent cells, and thus can be used to restore the function of muscle tissue that has decreased in function due to aging, etc.

The invention belongs to the technical field of biological medicines, and particularly relates to lipid nanoparticles as well as a preparation method and application thereof. The invention discloses a lipid nanoparticle. The material of the lipid nanoparticle comprises phospholipid and cholesterol. According to the invention, a lipid nano-carrier delivery system entrapped with apoptotic protein Bax is prepared through a microfluidic technology, and high encapsulation rate and stable delivery of protein drugs are realized. The nano-carrier delivery system capable of actively encapsulating the lipidosome realizes targeted delivery to senescent cells in vivo, so that senescent cell apoptosis is effectively induced, the proportion of senescent cells in tissues is reduced, and a new thought and means are provided for anti-aging treatment.

The application belongs to the technical field of functional polypeptides, and particularly relates to an active peptide for senescent cells and a preparation method thereof, wherein the active peptide is obtained by molecular docking simulation screening and optimization with a helical structure segment in an IL-6R protein combined with a gp130 protein as a polypeptide template; the active peptide after functional optimization contains an FF unit driving nano self-assembly, a GFLG unit capable of being specifically cut by a lysosome protease highly expressed in a microenvironment of senescent cells, and an RYFQKWEKLRNQ unit generating high affinity with an IL-6 / IL-6R / gp130 complex; the designed active peptide itself has anti-aging activity and can also be used for synergistic delivery of drugs, and has a broad application prospect.

The application belongs to the technical field of biological medicine, and particularly relates to an anti-aging ergothioneine composition for improving mitochondrial function and a preparation method thereof. The composition comprises the following components: ergothioneine, sea hao polysaccharide and entada extract. The ergothioneine has good mitochondrial targeted antioxidant activity, can up-regulate the expression of Sirt1 to activate PGC-1a, and promote mitochondrial biosynthesis; the sea hao polysaccharide is helpful to restore mitochondrial function, promote the generation of mitochondrial high-energy phosphoric compounds, improve cell activity and energy supply for regeneration, and can up-regulate the expression of key genes for mitochondrial biosynthesis and ATP synthase related genes. The entada extract can synergize with the ergothioneine and the sea hao polysaccharide, significantly down-regulate the expression of aging related proteins such as p53, p21 and p16 in cells, simultaneously inhibit the transcription of aging related genes, and has a good protective effect on aging cells.

The technology relates in part to compositions containing a cell penetrating peptide that can be used to selectively reduce a senescent cell population. The technology also relates to methods of treatment of ageing and ageing-associated diseases using a cell penetrating peptide to selectively reduce a senescent cell population.

The application discloses an engineered umbilical cord stem cell and application thereof in preparation of anti-aging drugs and medical beauty products. The application constructs an engineered cell system with high anti-aging function by designing a fusion polypeptide TAT-SIRT1-SOD (SEQ ID NO: 1) and an anti-p16INK4a monoclonal antibody (mAb-p16) to cooperatively modify the umbilical cord stem cell, and combining a 3D dynamic culture technology. The fusion polypeptide is mediated to cross the membrane by a TAT cell-penetrating peptide, activates SIRT1 and removes mitochondrial ROS; the mAb-p16 is specifically combined with p16INK4a on the surface of a senescent cell, and removes the senescent cell through an ADCC effect. Experiments show that the engineered umbilical cord stem cell can increase the removal rate of the senescent cell by 86.1%, increase the SOD activity by 300%, significantly inhibit the secretion of an inflammatory factor IL-6, and increase the skin collagen density by 148% and reduce the wrinkle depth by 67% in an animal model. The application provides a novel and efficient technical scheme for anti-aging drugs and medical beauty products.

The invention provides a linear or cyclic polypeptide and a derivative or analogue thereof, wherein the linear or cyclic polypeptide is used for mobilizing a stress-inducing protein (sestrin) from GATOR / mTOR to sMAC in a non-aging cell; the polypeptide comprises or consists of an amino acid sequence derived from a stress-inducing protein or a truncated sequence thereof. These polypeptides are useful in the treatment of conditions requiring immediate intervention, such as acute diseases, sepsis caused by pathogen infection, or anaphylaxis, such as allergic shock, as immunotherapeutic agents for the treatment of cancer, and for autoimmune diseases.

Senescent cells are implicated in aspects of age-related decline in health and may contribute to certain diseases. Embodiments include formulations and methods for promoting longevity and treating a senescence associated disease or disorder. Applicants present three distinct classes and multiple associated therapeutic molecules that can function alone or in combination with the other molecules. The classes include transcription regulators, lipid intermediates and microRNAs. Additional embodiments include methods of promoting longevity by administering GRAS substances.

Provided is the use of NKG2D-CD3 and NKG2D-CD16 cell adapter molecules in the removal of aging cells and the treatment of aging-cell-accumulation-related diseases, wherein the cell adapter molecules comprise an NKG2D extracellular domain, a connection segment, and a CD3 or CD16 binding domain. The death of aging cells having high expression of NKG2D ligand is efficiently induced by means of bridging aging cells and immune cells, and thus the cell adapter molecules of the present application can be used for removing aging cells expressing the NKG2D ligand and treating aging-related diseases.

The invention discloses a targeted multi-channel synergistic anti-aging composition as well as a preparation method and application thereof, and belongs to the technical field of functional foods and biological medicines. According to the composition disclosed by the invention, ginsenoside, a hawthorn polyphenol-chitosan phospholipid complex and spina date seed total saponins are taken as core active ingredients, and a specific Senlytics active ingredient and a natural mTOR inhibitor are compounded, so that the synergistic regulation of five anti-aging pathways, namely Sirtuins activation, mTOR inhibition, mitochondrial autophagy activation, CD38 inhibition and senescent cell removal, can be realized at the same time. The composition is natural in raw material source, high in safety and good in stability, can be prepared into various dosage forms such as capsules, solid beverages and oral liquid, is suitable for daily anti-aging and sub-health conditioning, and has wide application prospects in the fields of anti-aging health foods and biological medicines.

Compositions of matter, devices, and treatment protocols for reducing deleterious effects of senescent cells in a mammal. The invention provides extracorporeal devices capable of removing, in some cases selectively, senescence associated factors including small molecules, proteins, lipoproteins, as well as in some embodiments extracellular vesicles including exosomes, apoptotic bodies, or cellular released particles. Extracorporeal removal of senescent cell associated factors is performed to augment effects of senolytic therapy. Removal of senescence associated factors is performed to enhance efficacy of regenerative medicine interventions.

This invention discloses a mitochondrial-targeted nanomaterial for senescent cells and its application in anti-aging. The material is a nucleic acid aptamer-tetrahedral DNA, mainly assembled from four single-stranded DNA sequences, SEQ ID Nos. 1-4. Preparation involves first hybridizing the four single-stranded DNA sequences, then concentrating them to obtain aptamer-modified tetrahedra, which are then coupled with tannic acid (TA) via a Mann reaction in the presence of formaldehyde to obtain the Apt-tFNAs-TA complex. Finally, it is incubated with excess catechins to obtain the final delivery material, Apt-tFNAs@catechin-TA. This invention's material exhibits good biocompatibility and skin tissue compatibility, significantly improving uptake efficiency and mitochondrial localization ability in senescent cells. It can effectively deliver polyphenolic compounds such as catechins and protocatechuic acid, improving mitochondrial function and addressing the technical problems of low delivery efficiency of active ingredients and insufficient targeted enrichment in senescent cells.

This invention discloses *Bifidobacterium longum* with anti-aging functions and its applications, belonging to the field of microbial technology. The *Bifidobacterium longum* BBS 02 provided by this invention can promote cell vitality and proliferation, inhibit the high activity of β-galactosidase in senescent cells, and inhibit the high expression of the cyclin-dependent kinase inhibitor gene Cdkn1a, thereby achieving an anti-aging effect. The *Bifidobacterium longum* BBS 02 can be used to prepare edible nutrients or skin nutrients.

This invention proposes a nucleic acid aptamer that specifically binds to human senescent dermal fibroblasts (HDFs), along with its screening, identification, and application. Specific aptamers exhibiting high targeting specificity to human senescent HDFs were screened using Cell-SELEX technology. The three selected candidate aptamers showed binding rates of 57.5%, 86.2%, and 50.7% to senescent HDF cells within the same timeframe, respectively, demonstrating high specificity and targeted binding ability. Furthermore, the aptamer possesses potential for detecting, imaging, and regulating the function of senescent cells, successfully providing a new direction for targeted anti-aging interventions and therapeutic applications.

The present application belongs to the technical field of stem cell exosome preparation. More specifically, it relates to adipose-derived stem cells (ADSCs), conditioned medium (CM) thereof, and preparation method and use thereof in cosmetics and drugs. The present application provides a mesenchymal stem cell exosome preparation for delaying aging, wherein the exosome preparation is a conditioned medium obtained by culturing mesenchymal stem cells in a low-osmotic induction combined with epi-pen stimulation environment. Tests show that the conditioned medium can significantly enhance the proliferation and migration ability of senescent HSFs cells, reduce the expression of cell beta-galactosidase, reduce the expression of cell-related aging genes p16 and p53, and reduce the generation of intracellular ROS, and has a significant anti-aging effect.

The invention discloses a p16-OSKM transgenic mouse model and a reprogramming senescence cell construction method and application, and belongs to the technical field of cell biology and regenerative medicine. According to the method, a p16-OSKM hybrid mouse capable of specifically inducing an OSKM factor in a p16 high expression cell is obtained on the basis of hybridization of a p16-Ink4a-CreERT2 transgenic mouse, a Rosa26-CAG-LSL-rtTA3-IRES-mKate2 transgenic mouse and a Col1a1-TRE-OSKM-IRES-mCherry transgenic mouse. The selective activation of the OSKM factor in senescent cells with high expression of p16 can be realized by adding doxycycline into primary embryo fibroblasts separated from the mouse under an in-vitro culture condition, so that the senescent cells enter a cell cycle again and recover division and multiplication capacities. The technology provides an accurate model platform for basic research, and can be used for aging mechanism exploration, cell fate regulation and control, chronic disease treatment, development and screening of anti-aging drugs and the like.

The application discloses an engineered exosome targeting human urokinase-type plasminogen activator receptor uPAR and a preparation method and application thereof. Firstly, a high-affinity anti-human uPAR single-domain antibody VHH is prepared; then, a human umbilical cord mesenchymal stem cell engineering cell line expressing a VHH-PTGFRN fusion protein is constructed, and the engineered exosome is prepared and purified by combining three-dimensional hypoxic culture, chemical induction and size-exclusion chromatography technology. The engineered exosome comprises four comparative samples, wherein the core sample Exo^(VHH / miR) can simultaneously display the anti-uPAR VHH on the membrane surface to realize targeted delivery and enrich miR-193b-3p in the chamber to realize gene silencing, and the synergistic effect of the two can efficiently remove the uPAR high-expression senescent cells and inhibit the senescence-associated secretory phenotype SASP. The engineered exosome has the advantages of standardized preparation process, high yield and high purity, strong targeting, excellent curative effect and good safety, and can be used for preparing a treatment preparation for anti-aging and aging-related diseases, and has important clinical application value.

A system can be used to determine properties of a wellbore treatment fluid. The system can include a rotational system defining an axis of rotation and an aging cell. The aging cell can be positioned in the rotational system to rotate about the axis of rotation. The aging cell can include a housing, a sensor shaft, and a sensor. The housing can define an interior region of the aging cell to receive a wellbore treatment fluid. The sensor shaft can be at an angle from the axis of rotation and can be coupled to the interior region to transmit electronic signals about the wellbore treatment fluid. The sensor can be positioned on the sensor shaft to detect the electronic signals while the aging cell rotates about the axis of rotation, and the electronic signals can be used to determine the properties of the wellbore treatment fluid.

The invention discloses an application of loperamide in preparation of a medicine for treating osteoporosis, and belongs to the field of development of new application of medicines. Loperamide has the effects of inhibiting aging, increasing osteogenic differentiation of bone marrow mesenchymal stem cells and preventing osteoporosis of aged and postmenopausal mice; meanwhile, at the cellular level, loperamide can reduce expression of senescence factors in mouse mesenchymal stem cells, promote senescence cell apoptosis and inhibit cell senescence; and a new choice is provided for the treatment of senescence-related osteoporosis drugs.

The invention belongs to the technical field of biological medicine, and particularly relates to application of valproic acid in preparation of medicine for preventing and / or treating lung fibroblast and lung tissue senescence, the medicine induces the senescent lung fibroblast to excessively accumulate active oxygen in the cell, so that excessive autophagy of the cell is induced, senescent cell apoptosis is caused, and the effect of preventing and / or treating lung fibroblast and lung tissue senescence is achieved. And finally, the lung aging is relieved. The invention provides a new medicine source for preventing, intervening, delaying and researching aging of lung fibroblasts and lung tissues. The medicine for promoting apoptosis of aging cells in vitro or in the lung tissues, provided by the invention, is safe, relatively strong in pharmacological action, small in side effect and definite in curative effect.

The application provides use of FAP protein in preparation of reagents for inhibiting or removing senescent cells, and relates to the field of biological medicines. Development of anti-aging therapies requires senescent cell markers with high sensitivity and specificity, and due to the great heterogeneity of senescent cells, there is still a lack of in-vivo senescent cell markers which are widely present in various tissues and have high sensitivity and specificity. The application provides use of FAP protein in preparation of reagents for inhibiting or removing senescent cells, and FAP is expressed in senescent cells in various senescence diseases, and the pathogenic effect of senescent cells is removed or inhibited by means of targeted recognition of FAP protein, thereby providing a new idea for preparation of reagents for removing senescent cells.

The invention belongs to the technical field of biological medicines, and discloses application of beta-elemonic acid or a derivative or pharmaceutically acceptable salt thereof in preparation of medicines for regulating cell senescence and preventing and / or treating senescence-related diseases, including application as a cell senescence regulator (especially a senescence cell scavenger), and application of beta-elemonic acid or a derivative or pharmaceutically acceptable salt thereof in preparation of medicines for regulating cell senescence and preventing and / or treating senescence-related diseases. The invention also relates to application of the compound in preparation of medicines for preventing and / or treating diseases (such as organ fibrosis diseases and metabolic diseases) driven by cell aging pathology. In-vivo and in-vitro experiments prove that beta-EA can significantly reduce the number of SA-beta-gal positive senescence cells and down-regulate the expression of a core senescence marker protein p21 no matter in an in-vitro cell model or in an in-vivo pathological tissue. The invention also proves that beta-EA can reverse the degree of cell fibrosis, inhibits the transcriptional activity of an epithelial-mesenchymal transition pathway, has remarkable anti-fibrosis activity, and can be applied to treatment of organ fibrosis and other senescence-driven diseases.

The present invention relates to an anti-aging composition containing a Magnolia officinalis extract or magnolol, honokiol and 4-O-methlyhonokiol compounds. The extract or compound restores mitochondrial functions of senescent cells, reduces damaged DNA in cells, and restores senescent cells to a youthful cell state, and thus can be effectively used as a multifunctional cosmetic composition, a pharmaceutical composition, or a health functional food for inhibiting aging.

The invention discloses an ovarian anti-aging cell biological agent and a preparation method and application thereof, and belongs to the technical field of biology, ovarian stem cells and mulberry-source specific polypeptides SEQ ID NO.1 and SEQ ID NO.2 are compounded to obtain the biological agent, a cell repair and molecular regulation dual mechanism is formed, animal experiments show that the efficiency of promoting E2 secretion and inhibiting FSH secretion of the biological agent is improved, and the biological agent has a good application prospect. Moreover, the survival rate of follicles under a microscope is remarkably improved, and a relatively good treatment prospect is shown in the aspect of ovarian aging resistance. Meanwhile, mulberry with homology of medicine and food is adopted to replace polygonum multiflorum to extract active ingredients, and the risk of hepatotoxicity is avoided.

The technical field of the application is a device for medical, oral or dental hygiene. The application discloses a hydrogel material and a preparation method and application thereof. The preparation method of the hydrogel material comprises: preparing a ZnSe / rGO heterojunction by a hydrothermal method through ZnSe and rGO, wherein the ZnSe is a semiconductor material zinc selenide, and the rGO is a conductor material reduced graphene oxide; and uniformly dispersing the ZnSe / rGO heterojunction in a GelMA matrix, and loading and fixing the ZnSe / rGO heterojunction on the GelMA to obtain a hydrogel material Z / r@G, wherein Z refers to ZnSe, r refers to rGO, and G refers to GelMA, and the GelMA is methacrylated gelatin. The application develops a preventive strategy capable of delaying or reducing cell aging, which can not only avoid the influence of excessive removal of aged cells on later bone repair, but also widely exert an anti-aging effect.

The invention relates to the technical field of biological medicines, and discloses application of methionine adenosine transferase 2A and related substances thereof in preparation of anti-aging products. The invention finds that methionine adenosine transferase 2A (MAT2A) can induce mitochondrial metabolism brittleness through HMGCS1-mediated ubiquinone synthesis, so that the methionine adenosine transferase 2A (MAT2A) plays an unreported metabolic part-time role in regulating cell senescence. The specific improvement of the expression quantity of the MAT2A gene in the pericyte is beneficial for improving the cell proliferation activity, the cell mitochondrial respiration level, the cell oxygen consumption rate, the cell total ATP level and the expression level of a nuclear morphological marker LamB1, and meanwhile, the senescence cell percentage and the expression level of a senescence marker P21 are reduced; related substances for improving expression of methionine adenylyltransferase 2A can be used for preparing anti-aging drugs.

The invention discloses an anti-aging two-factor composition based on epigenetic reprogramming and application thereof, and belongs to the technical field of biological medicine. The composition comprises a Wnt pathway small molecule activator Laduvilliub and an ERK pathway activator bFGF, and through synergistic activation of Wnt and ERK signal pathways, epigenetic reprogramming of senescent cells is induced, and senescence-related chromatin open change, histone modification imbalance and DNA methylation clock drift are significantly reversed. At the cellular level, the composition can reverse various senescence phenotypes, namely restoring multiplication capacity, down-regulating expression of senescence-related secretory phenotype factors, relieving DNA damage, improving telomerase activity and telomere length and increasing nucleofibrin. At an individual level (an old mouse model), the composition is injected in the intraperitoneal cavity, so that the cognitive ability and the exercise ability are remarkably improved, the aging pathological characteristics of multiple organs are reduced, and the aging-related gene expression profiles of the organs such as the liver and muscles are reversed. The double-factor composition can be applied to anti-aging drugs, health care products or cosmetics.

The invention designs a biosynthetic hydroxyapatite-based protein kinase B (Akt1) electrochemical sensor which is applied to Akt1 activity analysis in a skin cell aging process. Hydroxyapatite is biologically synthesized through bacillus subtilis and is uniformly deposited on the surface of a glassy carbon electrode by utilizing a potentiometric deposition method. The surface of the material contains rich phosphate groups and hydroxyl groups, can be combined with lanthanum ions, and provides a good interface for subsequent sensor detection. In order to detect the activity of Akt1, a substrate polypeptide containing three phosphorylation sites is designed. The Akt1 is subjected to phosphorylation of a substrate polypeptide, negative charges are increased, combination of the Akt1 and lanthanum ions on the surface of the electrode is enhanced, the impedance on the surface of the electrode is increased, and the activity of the Akt1 is reflected. And the unphosphorylated substrate polypeptide cannot be effectively attached and shows a relatively small impedance value. The accuracy of the sensor is verified by adopting an Akt1 inhibitor MK-2206. Human skin fibroblasts (GNHu49) are taken as a model, and research finds that the activity of Akt1 in senescent cells is remarkably reduced, so that an experimental basis is provided for researching the activity change of Akt1 and the change of cell functions in the skin senescence process. The invention provides a new technical means for skin aging research, anti-aging drug evaluation and cosmetic technology.